With new data about different aspects of schizophrenia being continually generated, it
becomes necessary to periodically revisit exactly what we know. Along with a need to review …

Abstract Background The glutamate (Glu) and gamma aminobutyric acid (GABA)
hypotheses of schizophrenia were proposed in the 1980s. However, current findings on …

Evidence suggests that neurometabolite alterations may be involved in the pathophysiology
of autism spectrum disorders (ASDs). We performed a meta-analysis of proton magnetic …

Excessive glutamate release has been linked to stress and many neurodegenerative
diseases. Evidence indicates abnormalities of glutamatergic neurotransmission or …

Background In terms of antipsychotic treatment response, patients with schizophrenia can
be classified into three groups: 1) treatment resistant to both non-clozapine (non-CLZ) …

Early response to antipsychotic medications is one of the most important determinants of
later symptomatic and functional outcomes in psychosis. Glutathione and glutamate have …

Exposure to maternal infection in utero increases the risk that offspring will develop
neurodevelopmental disorders such as autism spectrum disorder (ASD) and schizophrenia …

Glutamatergic excitotoxicity is hypothesised to underlie synaptic loss in schizophrenia
pathogenesis, but it is unknown whether synaptic markers are related to glutamatergic …

Background Abnormal glutamate and GABA (gamma-aminobutyric acid) levels have been
found in the early phase of schizophrenia and may underlie cognitive deficits. However, the …

Background Poor response to dopaminergic antipsychotics constitutes a major challenge in
the treatment of psychotic disorders and markers for non-response during first-episode are …